| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 86 | 2024 | 4654 | 6.400 |
Why?
|
| Drug Eruptions | 15 | 2021 | 256 | 5.690 |
Why?
|
| Melanoma | 58 | 2023 | 5317 | 4.090 |
Why?
|
| Lichenoid Eruptions | 4 | 2020 | 36 | 2.240 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2021 | 3251 | 1.960 |
Why?
|
| Skin | 15 | 2022 | 1259 | 1.720 |
Why?
|
| Proto-Oncogene Proteins B-raf | 16 | 2022 | 1283 | 1.720 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 5 | 2024 | 61 | 1.710 |
Why?
|
| Panniculitis | 4 | 2017 | 58 | 1.680 |
Why?
|
| Skin Diseases | 8 | 2021 | 349 | 1.670 |
Why?
|
| Pemphigoid, Bullous | 2 | 2023 | 24 | 1.660 |
Why?
|
| Carcinoma, Merkel Cell | 8 | 2023 | 155 | 1.630 |
Why?
|
| Mycosis Fungoides | 11 | 2024 | 320 | 1.620 |
Why?
|
| Melanocytes | 11 | 2021 | 219 | 1.590 |
Why?
|
| Immunohistochemistry | 38 | 2023 | 7548 | 1.400 |
Why?
|
| Antineoplastic Agents, Immunological | 8 | 2021 | 1249 | 1.390 |
Why?
|
| Biomarkers, Tumor | 31 | 2023 | 10331 | 1.280 |
Why?
|
| Ipilimumab | 6 | 2018 | 710 | 1.250 |
Why?
|
| Antineoplastic Agents | 17 | 2021 | 14289 | 1.230 |
Why?
|
| Antibodies, Monoclonal | 8 | 2024 | 4367 | 1.200 |
Why?
|
| Sweat Gland Neoplasms | 3 | 2024 | 71 | 1.180 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 3 | 2019 | 259 | 1.150 |
Why?
|
| Granuloma | 3 | 2018 | 154 | 1.150 |
Why?
|
| Neoplasms, Second Primary | 5 | 2022 | 1350 | 1.070 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2024 | 69 | 1.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 7 | 2024 | 1048 | 1.050 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 3 | 2023 | 36 | 1.050 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2024 | 99 | 1.020 |
Why?
|
| Oximes | 3 | 2015 | 175 | 1.000 |
Why?
|
| Carcinoma, Skin Appendage | 1 | 2024 | 12 | 0.970 |
Why?
|
| Indoles | 5 | 2015 | 1009 | 0.880 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 5 | 2017 | 294 | 0.870 |
Why?
|
| Carcinoma, Ductal | 1 | 2024 | 145 | 0.860 |
Why?
|
| Nevus, Pigmented | 3 | 2017 | 104 | 0.790 |
Why?
|
| Aged | 73 | 2023 | 70117 | 0.790 |
Why?
|
| Humans | 156 | 2024 | 261506 | 0.780 |
Why?
|
| Nevus | 4 | 2023 | 107 | 0.770 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2021 | 33 | 0.770 |
Why?
|
| Sarcoma, Myeloid | 2 | 2018 | 95 | 0.760 |
Why?
|
| Imidazoles | 3 | 2015 | 999 | 0.730 |
Why?
|
| Biopsy | 21 | 2023 | 3443 | 0.720 |
Why?
|
| Immunity, Innate | 3 | 2023 | 677 | 0.710 |
Why?
|
| Sulfonamides | 5 | 2015 | 1823 | 0.700 |
Why?
|
| Karyopherins | 1 | 2020 | 136 | 0.680 |
Why?
|
| DNA Mutational Analysis | 7 | 2022 | 2283 | 0.670 |
Why?
|
| Acantholysis | 1 | 2018 | 8 | 0.670 |
Why?
|
| Adenoma | 1 | 2024 | 716 | 0.660 |
Why?
|
| Male | 92 | 2023 | 123000 | 0.650 |
Why?
|
| Exanthema | 1 | 2020 | 211 | 0.650 |
Why?
|
| Lymphomatoid Papulosis | 4 | 2023 | 68 | 0.640 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2021 | 272 | 0.640 |
Why?
|
| Organic Chemicals | 1 | 2018 | 113 | 0.640 |
Why?
|
| Erythema Nodosum | 1 | 2017 | 15 | 0.630 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2021 | 301 | 0.620 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2017 | 166 | 0.620 |
Why?
|
| Psoriasis | 4 | 2021 | 126 | 0.620 |
Why?
|
| Diagnosis, Differential | 23 | 2023 | 4744 | 0.610 |
Why?
|
| Monocytes | 2 | 2019 | 788 | 0.590 |
Why?
|
| Middle Aged | 72 | 2023 | 86204 | 0.590 |
Why?
|
| Carcinoma, Squamous Cell | 13 | 2021 | 5437 | 0.580 |
Why?
|
| Sarcoidosis | 1 | 2018 | 112 | 0.580 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2024 | 962 | 0.570 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2016 | 25 | 0.560 |
Why?
|
| Paget Disease, Extramammary | 3 | 2023 | 55 | 0.560 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 591 | 0.540 |
Why?
|
| Wilms Tumor | 1 | 2018 | 292 | 0.540 |
Why?
|
| Mutation | 20 | 2023 | 15179 | 0.530 |
Why?
|
| Nevus, Blue | 3 | 2023 | 40 | 0.530 |
Why?
|
| Aged, 80 and over | 39 | 2023 | 29902 | 0.510 |
Why?
|
| Calcinosis | 1 | 2018 | 423 | 0.510 |
Why?
|
| Female | 82 | 2023 | 141928 | 0.500 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 3230 | 0.500 |
Why?
|
| Telomerase | 3 | 2023 | 525 | 0.480 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 2341 | 0.480 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 1879 | 0.480 |
Why?
|
| Ki-1 Antigen | 4 | 2023 | 182 | 0.470 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2013 | 23 | 0.450 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 2 | 2013 | 64 | 0.440 |
Why?
|
| Sezary Syndrome | 2 | 2011 | 159 | 0.440 |
Why?
|
| Histiocytoma, Benign Fibrous | 2 | 2014 | 73 | 0.430 |
Why?
|
| Neoplasms | 7 | 2022 | 15193 | 0.420 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2012 | 82 | 0.420 |
Why?
|
| Keratinocytes | 4 | 2016 | 241 | 0.410 |
Why?
|
| Thyroid Neoplasms | 4 | 2019 | 1866 | 0.410 |
Why?
|
| Adult | 53 | 2022 | 77950 | 0.410 |
Why?
|
| Immunocompromised Host | 3 | 2016 | 698 | 0.400 |
Why?
|
| Cell Differentiation | 4 | 2023 | 4078 | 0.400 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2022 | 387 | 0.400 |
Why?
|
| Immunotherapy | 4 | 2022 | 3341 | 0.380 |
Why?
|
| Predictive Value of Tests | 13 | 2021 | 4892 | 0.380 |
Why?
|
| Histones | 3 | 2014 | 1466 | 0.380 |
Why?
|
| Sarcoma | 3 | 2021 | 1725 | 0.370 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 332 | 0.370 |
Why?
|
| Scalp | 3 | 2017 | 156 | 0.360 |
Why?
|
| Mutation, Missense | 1 | 2015 | 1152 | 0.360 |
Why?
|
| Neoplasm Staging | 15 | 2020 | 13658 | 0.350 |
Why?
|
| Piperidines | 3 | 2021 | 1035 | 0.340 |
Why?
|
| Cell Nucleus | 1 | 2014 | 1620 | 0.340 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2023 | 2232 | 0.340 |
Why?
|
| Lymphatic Metastasis | 13 | 2020 | 4844 | 0.330 |
Why?
|
| Mitosis | 4 | 2016 | 615 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2021 | 15862 | 0.330 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2020 | 216 | 0.320 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2011 | 366 | 0.320 |
Why?
|
| Smallpox Vaccine | 1 | 2007 | 43 | 0.310 |
Why?
|
| Treatment Outcome | 17 | 2021 | 32848 | 0.300 |
Why?
|
| Vascular Neoplasms | 2 | 2018 | 114 | 0.300 |
Why?
|
| Dermatitis | 2 | 2020 | 60 | 0.300 |
Why?
|
| Injections | 1 | 2007 | 285 | 0.290 |
Why?
|
| Vulvar Neoplasms | 2 | 2016 | 236 | 0.290 |
Why?
|
| Histiocytes | 2 | 2018 | 94 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2020 | 1823 | 0.280 |
Why?
|
| Melanoma-Specific Antigens | 2 | 2016 | 82 | 0.280 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2018 | 388 | 0.270 |
Why?
|
| Cicatrix | 1 | 2007 | 208 | 0.270 |
Why?
|
| Adenocarcinoma, Sebaceous | 2 | 2016 | 65 | 0.270 |
Why?
|
| Kidney Neoplasms | 2 | 2018 | 3022 | 0.270 |
Why?
|
| Ki-67 Antigen | 2 | 2018 | 666 | 0.260 |
Why?
|
| Eye Neoplasms | 2 | 2018 | 247 | 0.260 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 5112 | 0.250 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2016 | 2291 | 0.250 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2023 | 203 | 0.250 |
Why?
|
| Nectins | 1 | 2024 | 11 | 0.240 |
Why?
|
| Acitretin | 2 | 2021 | 12 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2020 | 10035 | 0.240 |
Why?
|
| Epidermis | 4 | 2017 | 188 | 0.240 |
Why?
|
| Eyelid Neoplasms | 2 | 2015 | 191 | 0.230 |
Why?
|
| Plasma Cells | 2 | 2022 | 192 | 0.230 |
Why?
|
| Blister | 1 | 2023 | 31 | 0.230 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2003 | 17 | 0.230 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2019 | 86 | 0.230 |
Why?
|
| Lymph Nodes | 3 | 2019 | 2967 | 0.230 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2022 | 489 | 0.230 |
Why?
|
| Dermis | 3 | 2017 | 65 | 0.220 |
Why?
|
| CTLA-4 Antigen | 2 | 2017 | 657 | 0.220 |
Why?
|
| Paget's Disease, Mammary | 1 | 2023 | 41 | 0.220 |
Why?
|
| Immunophenotyping | 6 | 2017 | 1681 | 0.220 |
Why?
|
| Pericardial Effusion | 1 | 2003 | 118 | 0.220 |
Why?
|
| Paraffin Embedding | 2 | 2014 | 226 | 0.220 |
Why?
|
| Young Adult | 18 | 2021 | 21445 | 0.220 |
Why?
|
| Prognosis | 16 | 2021 | 21713 | 0.220 |
Why?
|
| Complement System Proteins | 1 | 2023 | 139 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 1265 | 0.210 |
Why?
|
| Tick Bites | 1 | 2022 | 8 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 4757 | 0.210 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2022 | 20 | 0.210 |
Why?
|
| Nail Diseases | 1 | 2022 | 40 | 0.210 |
Why?
|
| Pseudolymphoma | 1 | 2022 | 22 | 0.210 |
Why?
|
| Urine | 1 | 2002 | 143 | 0.210 |
Why?
|
| Argyria | 1 | 2021 | 6 | 0.200 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 980 | 0.200 |
Why?
|
| Up-Regulation | 3 | 2024 | 2450 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 3981 | 0.200 |
Why?
|
| Cell Proliferation | 7 | 2021 | 7226 | 0.200 |
Why?
|
| Receptors, Pituitary Hormone | 1 | 2001 | 3 | 0.200 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2018 | 61 | 0.200 |
Why?
|
| Dermatofibrosarcoma | 1 | 2021 | 72 | 0.200 |
Why?
|
| Nails | 1 | 2021 | 36 | 0.200 |
Why?
|
| Angiofibroma | 1 | 2001 | 17 | 0.200 |
Why?
|
| Neuroectodermal Tumors | 1 | 2021 | 35 | 0.200 |
Why?
|
| Ploidies | 1 | 2001 | 248 | 0.190 |
Why?
|
| Langerhans Cell Sarcoma | 1 | 2020 | 15 | 0.190 |
Why?
|
| Fluocinonide | 1 | 2020 | 6 | 0.190 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 1294 | 0.190 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2023 | 1062 | 0.190 |
Why?
|
| Papillomaviridae | 3 | 2022 | 624 | 0.190 |
Why?
|
| Triamcinolone | 1 | 2020 | 20 | 0.190 |
Why?
|
| Keratolytic Agents | 1 | 2020 | 20 | 0.190 |
Why?
|
| Carcinoma, Small Cell | 1 | 2023 | 408 | 0.190 |
Why?
|
| Merkel cell polyomavirus | 2 | 2017 | 30 | 0.190 |
Why?
|
| Skin Ulcer | 2 | 2018 | 77 | 0.190 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2022 | 1415 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 129 | 0.190 |
Why?
|
| GATA3 Transcription Factor | 1 | 2021 | 146 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 198 | 0.180 |
Why?
|
| Pathology, Clinical | 1 | 2021 | 152 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 171 | 0.180 |
Why?
|
| Awareness | 1 | 2021 | 126 | 0.180 |
Why?
|
| Education, Distance | 1 | 2021 | 93 | 0.180 |
Why?
|
| Hypertrophy | 1 | 2020 | 162 | 0.180 |
Why?
|
| Lichen Planus | 1 | 2020 | 22 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2013 | 287 | 0.180 |
Why?
|
| Mitotic Index | 3 | 2016 | 162 | 0.180 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2021 | 324 | 0.170 |
Why?
|
| Genes, ras | 2 | 2013 | 667 | 0.170 |
Why?
|
| Ulcer | 1 | 2019 | 78 | 0.170 |
Why?
|
| Dermatology | 1 | 2020 | 70 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 8873 | 0.170 |
Why?
|
| Carcinosarcoma | 1 | 2020 | 146 | 0.170 |
Why?
|
| Azetidines | 1 | 2019 | 87 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2015 | 673 | 0.170 |
Why?
|
| Hemangiosarcoma | 2 | 2018 | 234 | 0.170 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 862 | 0.170 |
Why?
|
| Colitis | 1 | 2022 | 340 | 0.170 |
Why?
|
| Elastic Tissue | 1 | 2018 | 34 | 0.170 |
Why?
|
| Receptors, IgG | 1 | 2019 | 102 | 0.170 |
Why?
|
| Lymphatic Vessels | 2 | 2018 | 143 | 0.170 |
Why?
|
| Retrospective Studies | 15 | 2021 | 37905 | 0.160 |
Why?
|
| Sunlight | 1 | 2018 | 79 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2017 | 402 | 0.160 |
Why?
|
| Adenine | 1 | 2021 | 631 | 0.160 |
Why?
|
| B7-H1 Antigen | 3 | 2024 | 1022 | 0.160 |
Why?
|
| B7 Antigens | 1 | 2019 | 84 | 0.160 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 223 | 0.160 |
Why?
|
| Xanthomatosis | 1 | 2018 | 21 | 0.160 |
Why?
|
| Radiodermatitis | 1 | 2018 | 75 | 0.160 |
Why?
|
| Tumor Burden | 3 | 2019 | 1987 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2023 | 1664 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 406 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 551 | 0.160 |
Why?
|
| Osteonectin | 1 | 2018 | 53 | 0.160 |
Why?
|
| Conjunctival Neoplasms | 1 | 2019 | 120 | 0.160 |
Why?
|
| Dermoscopy | 1 | 2017 | 14 | 0.160 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2018 | 62 | 0.160 |
Why?
|
| Coccidioidomycosis | 1 | 2018 | 32 | 0.160 |
Why?
|
| Disease Progression | 9 | 2023 | 6682 | 0.160 |
Why?
|
| PUVA Therapy | 1 | 2017 | 34 | 0.160 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 1073 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2020 | 1146 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2018 | 3552 | 0.160 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2018 | 153 | 0.160 |
Why?
|
| Receptors, CCR4 | 1 | 2017 | 34 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 2315 | 0.150 |
Why?
|
| Chondrosarcoma | 1 | 2020 | 216 | 0.150 |
Why?
|
| Poroma | 1 | 2017 | 9 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2021 | 592 | 0.150 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2002 | 489 | 0.150 |
Why?
|
| Interleukin-17 | 1 | 2019 | 250 | 0.150 |
Why?
|
| Transcription Factors | 5 | 2023 | 5270 | 0.150 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 216 | 0.150 |
Why?
|
| RNA, Messenger | 3 | 2023 | 6150 | 0.140 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2013 | 142 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 179 | 0.140 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2016 | 42 | 0.140 |
Why?
|
| Dermatomycoses | 1 | 2016 | 42 | 0.140 |
Why?
|
| Chromosomes, Human, 6-12 and X | 1 | 2016 | 17 | 0.140 |
Why?
|
| Adolescent | 15 | 2021 | 31252 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2020 | 629 | 0.140 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 246 | 0.140 |
Why?
|
| Carcinoma | 4 | 2019 | 2578 | 0.140 |
Why?
|
| Subcutaneous Tissue | 2 | 2017 | 62 | 0.140 |
Why?
|
| Histoplasmosis | 1 | 2016 | 74 | 0.140 |
Why?
|
| Drosophila Proteins | 1 | 2003 | 858 | 0.140 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 11538 | 0.140 |
Why?
|
| DNA, Neoplasm | 2 | 2001 | 1910 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 2483 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2018 | 854 | 0.140 |
Why?
|
| Warts | 1 | 2015 | 19 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2017 | 311 | 0.140 |
Why?
|
| Muir-Torre Syndrome | 1 | 2015 | 18 | 0.140 |
Why?
|
| Phosphatidylethanolamine Binding Protein | 1 | 2015 | 7 | 0.140 |
Why?
|
| Forkhead Transcription Factors | 2 | 2024 | 778 | 0.130 |
Why?
|
| Dendritic Cells | 2 | 2017 | 1085 | 0.130 |
Why?
|
| Cellular Senescence | 2 | 2008 | 382 | 0.130 |
Why?
|
| Langerhans Cells | 1 | 2015 | 50 | 0.130 |
Why?
|
| Dermatitis, Photoallergic | 1 | 2015 | 5 | 0.130 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2018 | 604 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 671 | 0.130 |
Why?
|
| Skin Diseases, Viral | 1 | 2015 | 12 | 0.130 |
Why?
|
| HTLV-I Infections | 1 | 2015 | 16 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2021 | 2218 | 0.130 |
Why?
|
| Fingers | 1 | 2016 | 120 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 411 | 0.130 |
Why?
|
| Eczema | 1 | 2015 | 37 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 992 | 0.130 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 1664 | 0.130 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 973 | 0.130 |
Why?
|
| Staining and Labeling | 1 | 2016 | 429 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 589 | 0.120 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 882 | 0.120 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 4988 | 0.120 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2015 | 98 | 0.120 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2015 | 362 | 0.120 |
Why?
|
| Phenotype | 4 | 2023 | 6295 | 0.120 |
Why?
|
| Meningioma | 1 | 2017 | 289 | 0.120 |
Why?
|
| Immunodominant Epitopes | 1 | 2014 | 61 | 0.120 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 6009 | 0.120 |
Why?
|
| Freezing | 1 | 2014 | 59 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2020 | 1130 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 810 | 0.120 |
Why?
|
| Herpesvirus 3, Human | 1 | 2014 | 43 | 0.120 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2015 | 132 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2023 | 3869 | 0.120 |
Why?
|
| Necrosis | 1 | 2015 | 580 | 0.120 |
Why?
|
| Time Factors | 8 | 2021 | 12926 | 0.120 |
Why?
|
| Herpes Zoster | 1 | 2014 | 50 | 0.120 |
Why?
|
| Frozen Sections | 1 | 2014 | 105 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2016 | 864 | 0.120 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 426 | 0.120 |
Why?
|
| Cyclin D1 | 1 | 2015 | 576 | 0.110 |
Why?
|
| Leukemia | 1 | 2022 | 1635 | 0.110 |
Why?
|
| CD8 Antigens | 1 | 2013 | 170 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2017 | 889 | 0.110 |
Why?
|
| CD4 Antigens | 1 | 2013 | 170 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2021 | 1270 | 0.110 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 1360 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 1081 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2016 | 279 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2017 | 1586 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2017 | 441 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2023 | 5159 | 0.110 |
Why?
|
| Thigh | 1 | 2014 | 172 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2019 | 1048 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1217 | 0.110 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2012 | 31 | 0.110 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2018 | 2979 | 0.110 |
Why?
|
| MicroRNAs | 2 | 2016 | 2947 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2018 | 717 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 612 | 0.100 |
Why?
|
| Facial Dermatoses | 1 | 2012 | 26 | 0.100 |
Why?
|
| Neoplasm Seeding | 1 | 2012 | 66 | 0.100 |
Why?
|
| Niacinamide | 1 | 2013 | 421 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 1547 | 0.100 |
Why?
|
| Angiomatosis, Bacillary | 1 | 2011 | 9 | 0.100 |
Why?
|
| Leukopenia | 1 | 2012 | 151 | 0.100 |
Why?
|
| Oligodendroglioma | 1 | 2012 | 106 | 0.100 |
Why?
|
| Child | 11 | 2022 | 29154 | 0.100 |
Why?
|
| Risk Assessment | 6 | 2021 | 6869 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 528 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2020 | 1423 | 0.100 |
Why?
|
| Azathioprine | 1 | 2011 | 66 | 0.100 |
Why?
|
| Disease-Free Survival | 6 | 2020 | 10001 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 1242 | 0.100 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2017 | 1039 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 2 | 2017 | 3976 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 476 | 0.090 |
Why?
|
| Gene Expression | 1 | 2019 | 3570 | 0.090 |
Why?
|
| Fatal Outcome | 4 | 2019 | 829 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 984 | 0.090 |
Why?
|
| Child, Preschool | 7 | 2021 | 16273 | 0.090 |
Why?
|
| Apoptosis | 4 | 2022 | 7591 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 702 | 0.090 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 361 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 580 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 6915 | 0.090 |
Why?
|
| Alopecia | 1 | 2010 | 126 | 0.090 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2000 | 82 | 0.090 |
Why?
|
| Quinazolines | 1 | 2015 | 923 | 0.090 |
Why?
|
| Signal Transduction | 4 | 2021 | 11965 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2012 | 238 | 0.090 |
Why?
|
| Vimentin | 2 | 2020 | 253 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1763 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2008 | 5637 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2054 | 0.090 |
Why?
|
| Protein Kinases | 1 | 2013 | 874 | 0.090 |
Why?
|
| Gene Amplification | 2 | 2023 | 731 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2014 | 1271 | 0.080 |
Why?
|
| Prednisone | 1 | 2011 | 984 | 0.080 |
Why?
|
| Biopsy, Needle | 3 | 2019 | 1363 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1870 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 4975 | 0.080 |
Why?
|
| Antigens, Neoplasm | 3 | 2023 | 1506 | 0.080 |
Why?
|
| Methotrexate | 1 | 2011 | 999 | 0.080 |
Why?
|
| Lymphoma | 1 | 2016 | 1467 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1756 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 4821 | 0.070 |
Why?
|
| Risk Factors | 6 | 2021 | 17523 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 5767 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2014 | 2819 | 0.070 |
Why?
|
| Mohs Surgery | 1 | 2007 | 98 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 651 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2013 | 1154 | 0.070 |
Why?
|
| Histiocytosis, Sinus | 1 | 2006 | 86 | 0.060 |
Why?
|
| Histone Deacetylases | 1 | 2007 | 365 | 0.060 |
Why?
|
| Skin Diseases, Vascular | 1 | 2004 | 5 | 0.060 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2004 | 10 | 0.060 |
Why?
|
| Pyridines | 2 | 2022 | 1244 | 0.060 |
Why?
|
| CD3 Complex | 2 | 2016 | 314 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 2278 | 0.060 |
Why?
|
| Leg Ulcer | 1 | 2004 | 24 | 0.060 |
Why?
|
| Biomarkers | 4 | 2019 | 5047 | 0.060 |
Why?
|
| Gastric Mucosa | 2 | 2019 | 613 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 1375 | 0.060 |
Why?
|
| Glia Maturation Factor | 1 | 2024 | 8 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2019 | 495 | 0.060 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2024 | 37 | 0.060 |
Why?
|
| Age Distribution | 2 | 2019 | 698 | 0.060 |
Why?
|
| Infant | 4 | 2020 | 13310 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 2086 | 0.060 |
Why?
|
| PAX5 Transcription Factor | 1 | 2023 | 45 | 0.060 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2023 | 37 | 0.060 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2003 | 8 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2023 | 28 | 0.060 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2023 | 36 | 0.060 |
Why?
|
| Genes, p53 | 2 | 2020 | 1090 | 0.060 |
Why?
|
| SOXC Transcription Factors | 1 | 2023 | 53 | 0.060 |
Why?
|
| Superantigens | 1 | 2003 | 29 | 0.060 |
Why?
|
| Chaperonin 60 | 1 | 2003 | 47 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 7789 | 0.060 |
Why?
|
| Logistic Models | 3 | 2016 | 3441 | 0.060 |
Why?
|
| Lymphocyte Subsets | 1 | 2003 | 137 | 0.050 |
Why?
|
| Enterotoxins | 1 | 2003 | 112 | 0.050 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2003 | 78 | 0.050 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2003 | 87 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2330 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2003 | 241 | 0.050 |
Why?
|
| Culture Media | 1 | 2003 | 319 | 0.050 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2003 | 161 | 0.050 |
Why?
|
| Oxazoles | 1 | 2022 | 60 | 0.050 |
Why?
|
| Growth Substances | 1 | 2003 | 300 | 0.050 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 4849 | 0.050 |
Why?
|
| Adenolymphoma | 1 | 2002 | 27 | 0.050 |
Why?
|
| Cytarabine | 2 | 2019 | 1973 | 0.050 |
Why?
|
| Inclusion Bodies | 1 | 2022 | 76 | 0.050 |
Why?
|
| Salivary Ducts | 1 | 2002 | 56 | 0.050 |
Why?
|
| Adenosarcoma | 1 | 2001 | 16 | 0.050 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2002 | 63 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2003 | 174 | 0.050 |
Why?
|
| Chromatin | 1 | 2007 | 942 | 0.050 |
Why?
|
| Survival Rate | 3 | 2021 | 12221 | 0.050 |
Why?
|
| 12E7 Antigen | 1 | 2001 | 11 | 0.050 |
Why?
|
| Carcinoma, Papillary | 2 | 2015 | 584 | 0.050 |
Why?
|
| alpha-MSH | 1 | 2001 | 17 | 0.050 |
Why?
|
| Cell Division | 2 | 2003 | 2489 | 0.050 |
Why?
|
| Parotid Neoplasms | 1 | 2002 | 148 | 0.050 |
Why?
|
| Mice | 6 | 2022 | 34495 | 0.050 |
Why?
|
| World Health Organization | 1 | 2002 | 316 | 0.050 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 15694 | 0.050 |
Why?
|
| Animals | 8 | 2022 | 59536 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2003 | 419 | 0.050 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2002 | 137 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2003 | 354 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 269 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2003 | 558 | 0.050 |
Why?
|
| Clobetasol | 1 | 2020 | 9 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3821 | 0.050 |
Why?
|
| Hyperpigmentation | 1 | 2020 | 32 | 0.050 |
Why?
|
| S100 Proteins | 1 | 2020 | 181 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 3578 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 4971 | 0.050 |
Why?
|
| Thioguanine | 1 | 2019 | 68 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 104 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 995 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 212 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2020 | 257 | 0.040 |
Why?
|
| Bone Marrow | 2 | 2017 | 2358 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2003 | 842 | 0.040 |
Why?
|
| Phthalazines | 1 | 2021 | 253 | 0.040 |
Why?
|
| beta Catenin | 1 | 2023 | 688 | 0.040 |
Why?
|
| Metronidazole | 1 | 2020 | 149 | 0.040 |
Why?
|
| Hand | 1 | 2020 | 170 | 0.040 |
Why?
|
| Asparaginase | 1 | 2019 | 184 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 259 | 0.040 |
Why?
|
| DNA Primers | 1 | 2001 | 1399 | 0.040 |
Why?
|
| Cathelicidins | 1 | 2018 | 25 | 0.040 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 49 | 0.040 |
Why?
|
| Epidermal Cyst | 1 | 2018 | 46 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2019 | 301 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2004 | 755 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 661 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 649 | 0.040 |
Why?
|
| Pyrroles | 1 | 2022 | 576 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2019 | 9244 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2001 | 577 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2021 | 428 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2022 | 966 | 0.040 |
Why?
|
| Cell Line | 2 | 2007 | 5114 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2003 | 904 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 1038 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 390 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 430 | 0.040 |
Why?
|
| Cadherins | 1 | 2020 | 660 | 0.040 |
Why?
|
| Splenomegaly | 1 | 2017 | 158 | 0.040 |
Why?
|
| DNA Replication | 1 | 2001 | 744 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2017 | 4804 | 0.040 |
Why?
|
| Esophageal Neoplasms | 2 | 2021 | 3168 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2021 | 509 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.040 |
Why?
|
| Azure Stains | 1 | 2016 | 11 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6207 | 0.040 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2016 | 47 | 0.040 |
Why?
|
| Leukemia, T-Cell | 1 | 2016 | 87 | 0.040 |
Why?
|
| Hemangioma | 1 | 2018 | 154 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 461 | 0.040 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2016 | 88 | 0.030 |
Why?
|
| Recurrence | 2 | 2020 | 4758 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 2018 | 187 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2003 | 1682 | 0.030 |
Why?
|
| Azacitidine | 1 | 2022 | 1149 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2001 | 1385 | 0.030 |
Why?
|
| Gastritis | 1 | 2019 | 373 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2003 | 1549 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2020 | 1544 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2017 | 224 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2017 | 299 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2004 | 1112 | 0.030 |
Why?
|
| Incidence | 2 | 2019 | 5673 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 486 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2018 | 383 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2021 | 2084 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 4320 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 650 | 0.030 |
Why?
|
| CD4-CD8 Ratio | 1 | 2015 | 58 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2017 | 1037 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2016 | 290 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 317 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2015 | 109 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 2016 | 224 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 169 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 3639 | 0.030 |
Why?
|
| Base Sequence | 1 | 2001 | 4917 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2019 | 493 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 521 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 400 | 0.030 |
Why?
|
| Cholangiocarcinoma | 1 | 2019 | 493 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2017 | 351 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2013 | 55 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 699 | 0.030 |
Why?
|
| Peptides | 1 | 2000 | 1479 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 5395 | 0.030 |
Why?
|
| Cytokines | 1 | 2003 | 2809 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2021 | 4307 | 0.030 |
Why?
|
| raf Kinases | 1 | 2013 | 81 | 0.030 |
Why?
|
| MART-1 Antigen | 1 | 2013 | 105 | 0.030 |
Why?
|
| Prurigo | 1 | 2012 | 6 | 0.030 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2012 | 8 | 0.030 |
Why?
|
| Keratosis, Seborrheic | 1 | 2012 | 9 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 700 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 190 | 0.030 |
Why?
|
| Everolimus | 1 | 2015 | 415 | 0.030 |
Why?
|
| Keratosis, Actinic | 1 | 2012 | 37 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 479 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 336 | 0.030 |
Why?
|
| Piperazines | 1 | 2021 | 2101 | 0.030 |
Why?
|
| Vidarabine | 1 | 2017 | 1341 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1053 | 0.030 |
Why?
|
| Keratitis | 1 | 2012 | 102 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 403 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 1959 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 833 | 0.020 |
Why?
|
| Remission Induction | 1 | 2017 | 3569 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2018 | 1824 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 986 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 1183 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 3472 | 0.020 |
Why?
|
| Mucinosis, Follicular | 1 | 2010 | 9 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 3203 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1331 | 0.020 |
Why?
|
| Urocortins | 2 | 2000 | 4 | 0.020 |
Why?
|
| Alopecia Areata | 1 | 2010 | 55 | 0.020 |
Why?
|
| Craniotomy | 1 | 2012 | 304 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1678 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 9180 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 1033 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 14551 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 2074 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 848 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1819 | 0.020 |
Why?
|
| Thoracic Wall | 1 | 2011 | 183 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 2390 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 14889 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1239 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2004 | 5542 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 1163 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2359 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 2173 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 1099 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 1271 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 2316 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 1399 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1516 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2007 | 62 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1742 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2007 | 83 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2992 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2007 | 125 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3045 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2006 | 119 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 8865 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 335 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 4298 | 0.020 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2007 | 287 | 0.020 |
Why?
|
| Raynaud Disease | 1 | 2004 | 10 | 0.020 |
Why?
|
| Nephrocalcinosis | 1 | 2004 | 17 | 0.020 |
Why?
|
| Calcium Oxalate | 1 | 2004 | 33 | 0.020 |
Why?
|
| Plasmapheresis | 1 | 2004 | 61 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 837 | 0.020 |
Why?
|
| United States | 1 | 2021 | 15433 | 0.010 |
Why?
|
| Debridement | 1 | 2004 | 123 | 0.010 |
Why?
|
| Genomics | 1 | 2014 | 2738 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4638 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 2004 | 173 | 0.010 |
Why?
|
| Neurons | 1 | 2014 | 2287 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 7551 | 0.010 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 1946 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5539 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 5178 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 1082 | 0.010 |
Why?
|
| X Chromosome | 1 | 2001 | 339 | 0.010 |
Why?
|
| Amphibian Proteins | 1 | 2000 | 3 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 2000 | 43 | 0.010 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2000 | 20 | 0.010 |
Why?
|
| Mesocricetus | 1 | 2000 | 114 | 0.010 |
Why?
|
| Hair Follicle | 1 | 2000 | 64 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2004 | 1914 | 0.010 |
Why?
|
| Peptide Hormones | 1 | 2000 | 75 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 2006 | 927 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2000 | 358 | 0.010 |
Why?
|
| Cricetinae | 1 | 2000 | 706 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2000 | 875 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2004 | 732 | 0.010 |
Why?
|
| Protein Binding | 1 | 2000 | 3438 | 0.010 |
Why?
|
| Rats | 1 | 2000 | 6086 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2000 | 6942 | 0.010 |
Why?
|